All In Biotech

NDA 020379 · Pfizer

Caverject

Alprostadil · Injection · Prostaglandin Analog; Prostaglandin E1 Agonist

Priority review

Last checked: Nov 20, 2026Latest source record: Dec 23, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Jul 6, 1995

Approved uses

1

Original approval plus efficacy supplements

Registered trials

145

40 Phase 3, 8 recruiting

FAERS reports

2,865

2,024 serious, 244 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 13, 2024.

CAVERJECT is a prostaglandin E1 agonist indicated • For the treatment of erectile dysfunction ( 1.1 ). • As an adjunct to other diagnostic tests in the diagnosis of erectile dysfunction ( 1.2 ). 1.1 Erectile Dysfunction CAVERJECT is indicated for the treatment of erectile dysfunction. 1.2 Diagnostic Test CAVERJECT is indicated as an adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.

Mechanism: Alprostadil (PGE1) is a prostaglandin with a wide variety of pharmacological actions including vasodilation and inhibition of platelet aggregation. Alprostadil induces erection by relaxation of trabecular smooth muscle and by dilation of cavernosal arteries by binding to its receptors and increasing intracellular cyclic adenosine monophosphate (cAMP) levels via modulation of adenylate cyclase. This leads to expansion of lacunar spaces and entrapment of blood by compressing the venules against the tunica albuginea, a process referred to as the corporal veno-occlusive mechanism. Alprostadil...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 6, 1995 Original approval · Type 3 - New Dosage Form · priority review
4 products under this application
  • CAVERJECT · ALPROSTADIL 0.04MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • CAVERJECT · ALPROSTADIL 0.02MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • CAVERJECT · ALPROSTADIL 0.005MG/VIAL · INJECTABLE, INJECTION · Discontinued
  • CAVERJECT · ALPROSTADIL 0.01MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Alprostadil" as an intervention, any sponsor and status, largest first.

All 145 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective638
  • off label use143
  • erection increased104
  • haemoglobin decreased83
  • lymphocyte count decreased79
  • pyrexia76
  • diarrhoea72
  • erectile dysfunction71
  • penile pain70
  • condition aggravated68
  • pain65
  • cardiac failure64

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200476
200591
2006126
200785
200887
200947
2010363
2011185
2012128
201382
201467
2015127
2016180
2017206
2018139
2019184
2020141
2021118
202299
202391
2024101
202574
202667

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 199 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.